Emilie Elliot1, Mimie Chirwa, Marta Boffito. 1. aSSAT, Chelsea and Westminster Hospital, London bUniversity of Liverpool, Liverpool cImperial College, London, UK.
Abstract
PURPOSE OF REVIEW: This review of recent published literature and data presented at scientific meetings on integrase stand transfer inhibitors (InSTIs) examines how these findings may impact on their future clinical use. RECENT FINDINGS: Elvitegravir (EVG), raltegravir (RAL) and dolutegravir (DTG) are InSTIs recommended as first-line options for treatment naive patients by the European AIDS Clinical Society, British HIV Association, International AIDS Society-USA and DHHS. InSTIs have gained a leading role in the management of HIV-1 because of increased viral suppression and maintaining undetectability with fewer side-effects.RAL 1200 mg once-daily (QD) has been shown to be noninferior to 400 mg BD, and the European Medicines Agency has approved QD RAL for review. RAL and DTG are not metabolized via cytochrome P450 (CYP) resulting in fewer drug interactions and less toxicity risk in patients receiving direct-acting antivirals and other coadministered medications.EVG is currently available as a single tablet regimen and requires cobisistat, a pharmacokinetic booster and CYP3A inhibitor to allow QD dosing. EVG will soon be available in combination with tenofovir alfenamide, which is as efficacious as tenofovir disoproxil fumarate, but offers better renal and bone outcomes.DTG has a high genetic barrier to resistance and has been the subject of a number of simplification and treatment failure trials and shown promise. There are some emerging reports of neuropsychiatric and gastrointestinal side-effects associated with DTG, which were not reported in clinical trials emphasizing the importance of real-life data.Carbotegravir, a long-acting InSTI, is currently in the pipeline of development. SUMMARY: All three InSTIs have impressive data on efficacy, tolerability and safety. The unique differences of each InSTI's pharmacokinetics and pharmacodynamics lend themselves to various clinical scenarios, enabling us as clinicians to provide better patient-centred care.
PURPOSE OF REVIEW: This review of recent published literature and data presented at scientific meetings on integrase stand transfer inhibitors (InSTIs) examines how these findings may impact on their future clinical use. RECENT FINDINGS:Elvitegravir (EVG), raltegravir (RAL) and dolutegravir (DTG) are InSTIs recommended as first-line options for treatment naive patients by the European AIDS Clinical Society, British HIV Association, International AIDS Society-USA and DHHS. InSTIs have gained a leading role in the management of HIV-1 because of increased viral suppression and maintaining undetectability with fewer side-effects.RAL 1200 mg once-daily (QD) has been shown to be noninferior to 400 mg BD, and the European Medicines Agency has approved QD RAL for review. RAL and DTG are not metabolized via cytochrome P450 (CYP) resulting in fewer drug interactions and less toxicity risk in patients receiving direct-acting antivirals and other coadministered medications.EVG is currently available as a single tablet regimen and requires cobisistat, a pharmacokinetic booster and CYP3A inhibitor to allow QD dosing. EVG will soon be available in combination with tenofovir alfenamide, which is as efficacious as tenofovir disoproxil fumarate, but offers better renal and bone outcomes.DTG has a high genetic barrier to resistance and has been the subject of a number of simplification and treatment failure trials and shown promise. There are some emerging reports of neuropsychiatric and gastrointestinal side-effects associated with DTG, which were not reported in clinical trials emphasizing the importance of real-life data.Carbotegravir, a long-acting InSTI, is currently in the pipeline of development. SUMMARY: All three InSTIs have impressive data on efficacy, tolerability and safety. The unique differences of each InSTI's pharmacokinetics and pharmacodynamics lend themselves to various clinical scenarios, enabling us as clinicians to provide better patient-centred care.
Authors: Rohan Gurjar; Laura Dickinson; Daniel Carr; Wolfgang Stöhr; Stefano Bonora; Andrew Owen; Antonio D'Avolio; Adam Cursley; Nathalie De Castro; Gerd Fätkenheuer; Linos Vandekerckhove; Giovanni Di Perri; Anton Pozniak; Christine Schwimmer; François Raffi; Marta Boffito Journal: Pharmacogenomics J Date: 2022-10-20 Impact factor: 3.245
Authors: Todd M Pollack; Hao T Duong; Thuy T Pham; Thang D Nguyen; Howard Libman; Long Ngo; James H McMahon; Julian H Elliott; Cuong D Do; Donn J Colby Journal: J Int AIDS Soc Date: 2019-03 Impact factor: 5.396
Authors: Chi-Hua Lu; Edward M Bednarczyk; Linda M Catanzaro; Alyssa Shon; Jia-Chen Xu; Qing Ma Journal: Curr Res Pharmacol Drug Discov Date: 2021-08-08
Authors: JoEllyn McMillan; Adam Szlachetka; Lara Slack; Brady Sillman; Benjamin Lamberty; Brenda Morsey; Shannon Callen; Nagsen Gautam; Yazen Alnouti; Benson Edagwa; Howard E Gendelman; Howard S Fox Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: Dario Cattaneo; Salvatore Sollima; Paola Meraviglia; Laura Milazzo; Davide Minisci; Marta Fusi; Carlo Filice; Cristina Gervasoni Journal: Drugs R D Date: 2020-06